Celltrion's inhaled COVID-19 treatment undergoes phase 1 clinical trial in Australia
Updated: 2021-10-22 09:42:23 KST
A COVID-19 treatment developed by South Korean pharmaceutical giant Celltrion is currently undergoing a clinical trial.
Its U.S. partner, Inhalon Biopharma, started administering an inhaled-version of Regkirona to participants in Australia this month.
A total of 24 healthy individuals will receive the antibody therapeutic in the first phase of the clinical trial, followed by a phase 2 trial by the end of the year.
In August, Celltrion received approval from Australia's drug regulator to conduct efficacy evaluation studies for its inhaled treatment.